Key facts
- This page summarizes David A. Melnick's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2022, 15:19.
David A. Melnick - 01 Feb 2022 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- SPRO
- Reported as of
- 01 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2022, 15:19:47 UTC
- Prior SEC filing
- 30 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tamara Joseph, Attorney-in-Fact for David A. Melnick
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David A. Melnick filed Form 4 for Spero Therapeutics, Inc. (SPRO) on 03 Feb 2022.
Change
- Previous filing in this sequence was filed on 30 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +38,014
- Change %
- +158%
- Price
- $0.000000
- Shares after
- 62,081
- Date
- 01 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +53,190
- Change %
- Price
- $0.000000
- Shares after
- 53,190
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 53,190
- Exercise price
- $11.18
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F2
Consists of 62,081 RSUs held by the Reporting Person.
Footnote F3
The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
SEC remarks
Exhibit 24.1 - Power of Attorney